24/7 Market News Snapshot 09 September, 2025 – Agenus Inc. (NASDAQ:AGEN)

September 9, 2025

DENVER, Colo., 09 September, 2025 (www.247marketnews.com) – (NASDAQ:AGEN) are discussed in this article.
Agenus Inc. has demonstrated significant market momentum today, with shares opening at $4.33 and climbing to $4.92, marking an impressive increase of 15.49% from the previous close of $4.26. This surge in stock pricing is accompanied by a trading volume of 777.47K, indicative of strong investor interest and potential bullish sentiment. Market analysts are observing technical indicators that may signal further strength, particularly with resistance levels to watch above $5.00. Moving averages and other indicators will be crucial in confirming the sustainability of this upward trajectory, positioning Agenus as a company of interest for traders focused on volatility and growth opportunities.

In parallel with its market activity, Agenus has made headway in the oncology space by announcing the availability of its investigational combination therapy, botensilimab plus balstilimab (BOT/BAL), for patients battling refractory microsatellite-stable metastatic colorectal cancer (mCRC) through a compassionate access program. This initiative showcases the company’s commitment to addressing the significant unmet medical needs of patients who have exhausted standard treatment options.

The French National Agency of Medicines and Health Products Safety (ANSM) has authorized the compassionate use of this therapy, enabling hospitals to provide coverage and reimbursement, thereby facilitating patient access. Garo Armen, Chairman and CEO of Agenus, commended the collaborative effort with ANSM and the Ministry of Health, emphasizing the critical nature of this development. He highlighted the challenges faced by mCRC patients, noting the limited options for those who do not respond to existing immunotherapies.

Emerging peer-reviewed evidence suggests that BOT/BAL may offer durable responses for this patient cohort, with impressive metrics such as a median overall survival of approximately 21 months and a two-year survival rate of around 42%. Looking ahead, Agenus aims to advance its global Phase 3 BATTMAN trial to further validate the efficacy of BOT/BAL and broaden access for patients internationally. As a leader in immuno-oncology, Agenus remains dedicated to innovating cancer therapies that enhance the body’s immune responses against tumors.

Related news for (AGEN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.